SSY Pharmaceutical Research Institute SSY Pharmaceutical Research Institute

Corporate email

中文/EN

简体中文

English

NEWS CENTER

Group Announcement

Media reports

Group News

Shijiazhuang No.4 Pharmaceutical’s Metronidazole Sodium Chloride Injection Has Passed Consistency Evaluation.

Category:

Group Announcement

Time：2021-03-15

The metronidazole sodium chloride injection produced by Shijiazhuang No.4 Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration to pass the evaluation of consistency in quality and efficacy for generic drugs. Among these, the 250ml:1.25g specification is the first domestically approved, while the 100ml:0.5g specification is the second domestically approved.

The metronidazole sodium chloride injection produced by Shijiazhuang No.4 Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration to pass the evaluation of consistency in quality and efficacy for generic drugs. Specifically, the 250ml:1.25g specification is the first domestically approved, while the 100ml:0.5g specification is the second domestically approved.
Metronidazole is a commonly used antibiotic primarily employed to treat or prevent systemic or localized infections caused by anaerobic bacteria, including anaerobic infections of the abdominal cavity, digestive tract, female reproductive system, and oral cavity.
As of now, Shijiazhuang Four Pharmaceutical has had 11 varieties and 16 specifications pass the consistency evaluation or be deemed as having passed the consistency evaluation.

 

Keywords:

Previous

Shi Si Yao Group Guangxiang Pharmaceutical has been recognized as the Cangzhou City Technology Innovation Center.

Second Public Notice of the Environmental Impact Assessment for the Azithromycin Capacity Expansion and Renovation Project of Hebei Guolong Pharmaceutical Co., Ltd.

Next

Previous:

Shi Si Yao Group Guangxiang Pharmaceutical has been recognized as the Cangzhou City Technology Innovation Center.

Next:

Second Public Notice of the Environmental Impact Assessment for the Azithromycin Capacity Expansion and Renovation Project of Hebei Guolong Pharmaceutical Co., Ltd.